Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel

Next Previous
Trial Profile

Motion Serifos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness During Travel

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Motion sickness
  • Focus Registrational; Therapeutic Use
  • Acronyms Motion Serifos
  • Sponsors Vanda Pharmaceuticals

Most Recent Events

  • 14 Mar 2025 According to Vanda Pharmaceuticals Media Release, Tradipitant New Drug Application (NDA) for motion sickness accepted for filing by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.
  • 13 Feb 2025 According to Vanda Pharmaceuticals Media Release, the New Drug Application for tradipitant for the treatment of motion sickness was submitted to the FDA in the fourth quarter of 2024.
  • 15 May 2024 According to Vanda Pharmaceuticals Media Release, the company expects to submit a New Drug Application (NDA) for tradipitant in the prevention of vomiting induced by motion to the U.S Food and Drug Administration (FDA) in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top